Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC

(AGN)
  Report
Delayed Quote. Delayed Nyse - 04/01 04:10:00 pm
174.9 USD   -1.24%
04/01ALLERGAN : Form 8.3 - -2-
DJ
04/01ALLERGAN : Form 8.3 -
DJ
04/01ABBVIE : Form 8.3 -
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc

share with twitter share with LinkedIn share with facebook
share via e-mail
02/21/2020 | 10:35am EDT
TIDMIRSH TIDM0Y7T 
 
 
   Ap19 
 
   FORM 8.3 
 
   IRISH TAKEOVER PANEL 
 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, 
TAKEOVER RULES, 2013 
 
   DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 
1% OR MORE 
 
 
   1. KEY INFORMATION 
 
 
 
 
Name of person dealing      Davidson Kempner Capital 
 (Note 1)                    Management LP 
--------------------------  ------------------------- 
Company dealt in            Allergan PLC 
--------------------------  ------------------------- 
Class of relevant security  US$0.0001 ordinary shares 
 to which the dealings 
 being disclosed relate 
 (Note 2) 
--------------------------  ------------------------- 
Date of dealing             2020-02-20 
--------------------------  ------------------------- 
 
 
   1. INTERESTS AND SHORT POSITIONS 
 
 
   1. Interests and short positions (following dealing) in the class of 
      relevant security dealt in (Note 3) 
 
 
 
 
                                      Long            Short 
---------------------------  -----------------  -------------- 
                             Number      (%)    Number     (%) 
---------------------------             ------             --- 
(1) Relevant securities      5,286,953  1.6070 
---------------------------  ---------  ------  --------  ---- 
(2) Derivatives (other 
 than options) 
---------------------------  ---------  ------  --------  ---- 
(3) Options and agreements 
 to purchase/sell 
---------------------------  ---------  ------  --------  ---- 
Total                        5,286,953  1.6070 
---------------------------  ---------  ------  --------  ---- 
 
 
 
   1. Interests and short positions in relevant securities of the company, 
      other than the class dealt in (Note 3) 
 
 
 
 
Class of relevant security:           Long          Short 
----------------------------  --------------  --------------- 
                              Number     (%)  Number      (%) 
----------------------------             ---              --- 
(1) Relevant securities 
----------------------------  --------------  --------------- 
 
  (2) Derivatives (other 
  than options) 
----------------------------  --------------  --------------- 
 
  (3) Options and agreements 
  to purchase/sell 
----------------------------  --------------  --------------- 
Total 
----------------------------  --------------  --------------- 
 
 
 
 
 
 
   Ap20 
 
 
   1. DEALINGS (Note 4) 
 
 
   1. Purchases and sales 
 
 
 
 
 
  Purchase/sale    Number of relevant securities    Price per unit 
                                                    (Note 5) 
---------------  -------------------------------  ---------------- 
Purchase         20,573                           198.4347 USD 
---------------  -------------------------------  ---------------- 
 
 
 
 
   1. Derivatives transactions (other than options transactions) 
 
 
 
 
Product    Nature of transaction  Number of relevant  Price per 
 name,      (Note 6)               securities          unit 
 e.g. CFD                          (Note 7)            (Note 5) 
---------  ---------------------  ------------------  --------- 
 
 
 
   1. Options transactions in respect of existing relevant securities 
 
 
   1. Writing, selling, purchasing or varying 
 
 
 
 
Product     Writing,      Number of       Exercise  Type,            Expiry  Option 
 name,       selling,      securities      price     e.g. American,   date    money paid/received 
 e.g. call   purchasing,   to which                  European                 per unit 
 option      varying       the option                etc.                     (Note 5) 
             etc.          relates (Note 
                           7) 
----------  ------------  --------------  --------  ---------------  ------  -------------------- 
 
 
 
   1. Exercising 
 
 
 
 
Product name,            Number of securities      Exercise price 
 e.g. call option                                   per unit (Note 
                                                    5) 
-----------------  --------------------------  ------------------- 
 
 
 
   1. Other dealings (including transactions in respect of new securities) 
      (Note 4) 
 
 
 
 
Nature of transaction        Details      Price per unit 
 (Note 8)                                  (if applicable) 
                                           (Note 5) 
---------------------  -------------  -------------------- 
 
 
 
 
 
 
 
   Ap21 
 
   2.       OTHER INFORMATION 
 
   Agreements, arrangements or understandings relating to options or 
derivatives 
 
   Full details of any agreement, arrangement or understanding between the 
person disclosing and any other person relating to the voting rights of 
any relevant securities under any option referred to on this form or 
relating to the voting rights or future acquisition or disposal of any 
relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
   Is a Supplemental Form 8 attached? (Note 9) 
YES/NO 
 
 
 
 
Date of disclosure             2020-02-21 
----------------------------  ------------ 
Contact name                  James Gange 
----------------------------  ------------ 
Telephone number              212 446 4029 
----------------------------  ------------ 
If a connected EFM, name 
 of offeree/offeror with 
 which connected 
----------------------------  ------------ 
If a connected EFM, state 
 nature of connection (Note 
 10) 
----------------------------  ------------ 
 
 
 
 
 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
04/01ALLERGAN : Form 8.3 - -2-
DJ
04/01ALLERGAN : Form 8.3 -
DJ
04/01ABBVIE : Form 8.3 -
AQ
04/01DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
04/01DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan plc
AQ
03/31ALLERGAN : Form 8.3 -
DJ
03/31DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
03/30ALLERGAN : Form 8.3 - -2-
DJ
03/30ALLERGAN : Form 8.3 -
DJ
03/30ALLERGAN : Form 8.3 - -2-
DJ
More news
Financials (USD)
Sales 2020 15 678 M
EBIT 2020 7 085 M
Net income 2020 192 M
Debt 2020 12 765 M
Yield 2020 1,70%
P/E ratio 2020 116x
P/E ratio 2021 43,1x
EV / Sales2020 4,48x
EV / Sales2021 4,06x
Capitalization 57 542 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | MarketScreener
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 193,50  $
Last Close Price 174,90  $
Spread / Highest target 45,8%
Spread / Average Target 10,6%
Spread / Lowest Target -10,2%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer & EVP
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-8.51%58 266
JOHNSON & JOHNSON-10.10%345 705
ROCHE HOLDING AG1.53%277 060
MERCK & CO., INC-18.86%195 141
NOVARTIS-14.15%187 703
PFIZER, INC.-18.96%181 075